

particularly advantageous. Certainly, in the situation of rare cancers, collaborative networking is indispensable, and, of course, all of this needs to be funded properly."

In order to develop effective clinical trials for patients with rare cancers, international cooperation of experts with complementary skills and knowledge are required to find new ways to treat these diseases. In this light, the recommendations put forth by Rare Cancers Europe were the result of a consensus reached through multi-disciplinary and multi-stakeholder discussions. Rare Cancers Europe is dedicated to putting rare cancers firmly on the European policy agenda, and the EORTC is among the Cooperating Organizations.

These recommendations cover clinical decision-making in rare cancers, study designs in rare cancers, surrogate end-points in rare cancers, and critical organizational aspects of clinical research in rare cancers. In effect, they represent a road map showing the way to design trials to test new treatments in [patients](#) with rare cancers.

Rare Cancers Europe's recommendations on the methodology for clinical studies in rare cancers are available in *Annals of Oncology*.

More information: www.dx.doi.org/10.1093/annonc/mdu459

Provided by European Organisation for Research and Treatment of Cancer

Citation: European consensus on methodological recommendations for clinical studies in rare cancers (2014, October 28) retrieved 20 April 2024 from <https://medicalxpress.com/news/2014-10-european-consensus-methodological-clinical-rare.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.